🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being described as a "major milestone" in the battle against drug-resistant strains of the pathogen, according to health experts.

A Worldwide Challenge

Cases of gonorrhoea are on the rise worldwide, with figures suggesting over 82 million instances per year. Notably increased rates are seen in Africa and nations within the WHO's designated area, which includes China and Mongolia to New Zealand. In England, cases have hit a record high, while infection numbers across Europe in 2023 were significantly elevated compared to figures for 2014.

“The authorization of new treatments for gonorrhoea is an important and timely advancement in the face of increasing worldwide cases, increasing antimicrobial resistance and the very limited treatment choices currently available.”

Public health authorities are increasingly worried about the surge in antibiotic-resistant strains. The WHO has listed it as a "critical concern". Recent surveillance found that the effectiveness of key first-line drugs like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Recent Therapies Gain Clearance

Zoliflodacin, also known as a brand name, was cleared by the American regulatory agency in recent days for treating gonorrhoea. This STI can lead to major issues, including infertility. Scientists anticipate that focused deployment of this new drug will help slow the emergence of superbugs.

Gepotidacin, originating from the drugmaker GSK, was also approved in close succession. This medication, which is employed against UTIs, was demonstrated in studies to be able to combat superbug versions of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin stemmed from a unique collaborative effort for antibiotic development. The charitable organization GARDP worked alongside the drug firm its industry partner to develop it.

“This authorization marks a huge turning point in the treatment of superbug gonorrhoea, which up to this point has been outpacing antibiotic development.”

Clinical Trial Results and Worldwide Availability

Based on data detailed in a prominent scientific publication, zoliflodacin eradicated the vast majority of uncomplicated infections. This establishes an equal footing with the typical regimen, which uses two antibiotics. The trial enrolled hundreds of participants from several countries including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its development partnership, GARDP has the authority to license and sell the drug in numerous developing nations.

Clinicians treating patients have voiced optimism. Access to a one-pill regimen such as this is described as a "revolutionary step" for public health efforts. This is deemed essential to reduce the burden of the disease for individuals and to halt the transmission of untreatable gonorrhoea worldwide.